1. In Vivo
  2. >>Market Intelligence

When It Comes To Pharma R&D ROI, Mid Pharma Companies Outperform

 
• By Amanda Micklus

Datamonitor Healthcare's measurement of pharma R&D return on investment finds that Mid Pharma companies outperform on an ROI index. The second in a two-part series evaluating R&D productivity.

IV1609_WordCloud_ROI_1200x675

Mid Pharma companies, defined by Datamonitor Healthcare as those with annual revenues of less than $10 billion, have done a much better job than their Big Pharma and Japan Pharma peers at launching new drugs. Based on an analysis of new product launches between 2011 and 2015, a group of successful blockbuster products on the market – including Gilead Sciences Inc.'s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), and Biogen Inc.'s Tecfidera (dimethyl fumarate) – have helped to contribute to an average $6 billion for Mid Pharma companies collectively in aggregate commercial sales for the first seven years of new product launches, including both actual and forecasted sales. In comparison, the Big Pharma peer set realized an average $4 billion, and Japan Pharma, $2 billion. (Also see "Pharma R&D Efficiency: Mid-Sized Companies Excel" - In Vivo, 29 August, 2016.)

However, reviewing aggregated historical and forecasted sales only paints part of the picture when evaluating R&D productivity. To take it...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Market Intelligence

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.